I
n this issue of Diabetes Care, Hawa et al.
(1) conclude that "the pathogenesis of antigen-specific antibodies in type 1 diabetes and type 2 diabetes is similar and p robably involves a chronic nonrandom antigen-driven polyclonal B-cell activation that is consistent with a Th1-type immune response." The data presented also indicate that what are now standard anti-islet autoantibody assays are not impro v e d with the use of antibody subclass specific reagents. These are reasonable conclusions c o n c e rning both autoimmune T-and B-cells and are derived from the study of GAD65 and IA-2 (ICA512) autoantibodies. Some conclusions are naturally firm e r than others. For instance, the finding that autoantibodies express both and immunoglobulin light chains is convincing evidence of a polyclonal immune response. Each B-cell clone pro d u c e s either or a n t i b o d i e s .
The finding that prediabetic subjects, new-onset type 1 diabetic patients, and patients with type 1 diabetes presenting as adults with "non-insulin-dependent diabetes" all express predominantly IgG1 antibodies is consistent with re p o rts of a p redominance of IgG1 antibodies in young infants (2). The lack of changes in the subclass of the autoantibodies may be influenced by the stage of disease analyzed. When anti-islet autoantibodies first a p p e a r, there is re p o rted variation in subclass expression (2). A lack of change in antibody subclasses at the onset of diabetes compared with several years before onset is consistent with chronic pro g re ssion to type 1 diabetes. To date, there is little evidence of an immunologic change at the time of presentation of diabetes. In humans, diabetes probably results fro m p ro g ressive immune destruction of -c e l l s (3). In animal models, there is controversy as to whether -cell destruction is c h ronic (4) or acute (5).
It is noteworthy that autoantibodies w e re measured to ascertain whether the T-cells orchestrating an immune re s p o n s e a re predominantly Th1-like (pro d u c i n g lymphokines such as -i n t e rf e ron and interleukin [IL]-2) or Th2-like (pro d u c i n g lymphokines such as IL-4 and IL-10). Antibodies are being measured because they are something we can now measure well. The presence of anti-islet antibodies reacting with defined antigens such as GAD65, IA-2, or insulin is the best parameter for distinguishing type 1A (immunemediated) from type 1B, or type 2 diabetes (6). At onset of diabetes, it might be the only parameter of utility because C-peptide levels frequently overlap norm a l ranges. Many children (particularly in U.S. minority populations) are now developing type 2 diabetes (7), and as illustrated in the a rticle by Hawa et al., many adults have type 1A diabetes. Presence of autoantibodies reacting with multiple islet antigens is highly predictive of pro g ression to diabetes and insulin dependence (8,9). The subclasses of antibodies, especially in humans, however, are an imprecise re f l e ction of T-cell lymphokine production (10). Measuring autoimmune T-cell re s p o n s e s is just beyond the limits of current technology (11). We will likely have to wait for better technologies for analyzing autoimmune T-cells. For example, specific reagents labeling autoimmune T-cell re c e ptors (e.g., HLA tetramers [12] ) are now used in animal models.
Though there are excellent assays for autoantibodies (13) , there is evidence that antibodies do not cause diabetes but are "footprints" reflecting the presence of T-cells, which are destroying islet -cells. In the future, both autoantibodies and autoimmune T-cells should be accessible to analysis. This should further our understanding of disease pathogenesis and provide better diagnostic and prognostic inform a t i o n .
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